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Case Report
We present a case of an African-American female in her mid 20s 
with a history of smoking and uncontrolled hypertension who 
presented with intermittent abdominal pain for three years. 
The patient had past medical history significant for hyperten-
sion, smoking, and depression and no family history of prema-
ture coronary artery disease. The patient additionally had no 
past medical history significant for various vasculitides, such as 
Kawasaki’s disease, Moyamoya disease, Williams syndrome, 
or any other pathology, which could have contributed to her 
clinical presentation. The patient had smoked three cigarettes 
a day for the past four years and drinks alcohol socially. She 
was on amlodipine 10 mg oral daily. She was sent from her pri-
mary medical doctor’s office after a renal ultrasound showed a 
hemodynamically significant left renal artery stenosis (RAS) 
in the mid aspect of the renal artery with a left resistive index 
of 0.3, left renal/aortic ratio of 3.91, and left mid renal artery 
velocity Sys (systolic)/Dias (diastolic) of 313/213.
The patient’s vital signs on admission showed a blood 
pressure of 166/105, heart rate of 75, respiratory rate of 16, 
and body temperature of 98.7 °F. The initial electrolyte pro-
file of the patient was as follows: sodium 137, potassium 3.8, 
chloride 105, bicarbonate 25, blood urea nitrogen (BUN) 9, 
creatinine 0.68, glucose 89, calcium 8.5, magnesium 1.9, and 
phosphorous 2.9. The renin assay was 1.4 ng/mL/hour and 
the plasma aldosterone concentration was 7.1 ng/dL and the 
left kidney size was 13.4 × 4.2 cm, while the right kidney size 
was 10.1 × 4.0 cm. The right renal velocity was 80 cm/second. 
Physical examination was within normal limits, and no 
abdo minal bruits were appreciated. She had a 2-dimensional 
echo cardiogram (2D Echo), which showed mildly increased 
left ventricular wall thickness with an ejection fraction of 65%. 
The electrocardiogram showed normal sinus rhythm with 
no significant abnormalities. The patient underwent a renal 
artery catheterization the subsequent day. Based on angiog-
raphy and subjective analysis, a severe 99% mid left RAS with 
significant poststenotic dilatation was appreciated. Initially, 
the interventionist decided to perform a balloon angioplasty. 
However, the patient was noted to have a gradient more than 
24 mmHg post angioplasty and hence a stent was also suc-
cessfully placed. Following the intervention, there was an 
excellent angiographic appearance with a 0% residual stenosis 
(Fig. 2). Following the procedure, the patient was instructed 
to continue her antihypertensive regimen of amlodipine 10 mg 
PO daily. After stenting, the patient’s blood pressure normal-
ized to 122/82 in the hospital prior to discharge. The patient 
initially agreed for a follow-up on an outpatient basis with 
her cardiologist; however, after several months, the patient 
failed to follow-up with her primary care physician as well as 
her cardiologist.
This patient illustrates a case of hypertension second-
ary to RAS not caused by fibromuscular dysplasia (FMD) 
that is more typical for this age group. This case is unique 
as it describes the case of a young female who presented 
with hypertension that was unusual for her age and risk fac-
tors, without any evidence of atherosclerotic disease or FMD 
on angiography, which completely resolved after balloon 
angioplasty with stent placement.
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discussion
Pathophysiology of RAs. RAS is best defined as the 
“narrowing of the renal arteries caused by heterogenous group 
of conditions including atherosclerosis, FMD, vasculitis, 
neurofibromatosis, congenital bands, and extrinsic compres-
sion and radiation”.1 Atherosclerosis is the most common 
cause accounting for 90% of the lesions causing obstruction to 
the arteries. The prevalence of Atherosclerotic Renal Artery 
Stenosis (ARAS) rises with age as well as with concomitant 
conventional cardiovascular risk factors. It is associated with 
hypertension and chronic kidney disease and seen in more 
than 40% of patients with peripheral vascular disease as well 
as 10%–14% of patients undergoing cardiac catheterization 
with renal angiography. In addition, “oxidative stress has been 
implicated in ischemic and hypertensive parenchymal renal 
injury related to ARAS”.1 “Historical data show that up to 
27% of patients with ARAS will develop chronic renal failure 
within 6 years; additionally, studies have revealed that it is a 
cause of end-stage renal disease in 14% of patients in whom 
dialysis was newly initiated”.1
Moreover, the pathophysiology of the renin-dependent 
hypertension in patients with RAS due to fibromuscular dys-
plasia was first outlined by Goldblatt in the 1930s. His work 
has been expanded on to propose three distinct phases of 
renovascular hypertension that have previously been estab-
lished in animal models. The stages include stage I (acute 
occlusion), stage II (occlusion for days/weeks), and stage III 
(occlusion prolonged for months). Elevated levels of both renin 
and angiotensin II characterize stages I and II. These elevated 
levels lead to elimination of obstruction and therefore in turn 
lead to normalization of both blood pressure and plasma renin/
angiotensin II levels.1 In contrast, in stage III, plasma renin/
angiotensin levels are no longer elevated and elimination of the 
obstruction does not lead to normalization of blood pressure”.1
Fibromuscular dysplasia. FMD is characterized by 
abnormal cell growth in the walls of arteries of the body. The 
majority of patients diagnosed with FMD are females with 
data from the United States FMD patient registry, suggest-
ing that patients are typically diagnosed in their early 50s.2 
FMD most commonly affects the renal, carotid, and verte-
bral arteries, and it is classified according to the layer of artery 
wall most involved.2 The most common is medial fibroplasia. 
A number of theories have been proposed regarding its cause 
including environmental factors, such as smoking, estrogen, 
as well as genetic factors; however, it continues to be an area of 
investigation.2 Signs and symptoms of FMD in the renal vas-
culature include high blood pressure, abdominal bruits, renal 
artery aneurysm, and renal artery dissection. Catheter-based 
angiography is the most accurate imaging technique, and 
angioplasty is recommended for patients with renal artery 
FMD who have uncontrollable blood pressure, intolerance to 
medications, or declining kidney function.2
Atherosclerotic renal artery stenosis. ARAS most com-
monly contains the ostium and the proximal third of the renal 
artery, as well as the adjoining aorta.1 However, segmental 
and diffuse intrarenal atherosclerosis may also be appreciated, 
especially in severe cases. On the basis of the American Heart 
Association, there are several clinical clues that help diagnose 
ARAS. These include the following:
1. Onset of hypertension before 30 years old or severe 
hypertension after 55 years old (Class I, level of evidence 
[LOE] B);
2. Accelerated, resistant, or malignant hypertension (Class 
I, LOE C);
3. Development of new azotemia or worsening renal func-
tion after administration of an angiotensin-converting 
enzyme inhibitor or angiotensin receptor blocker (Class I, 
LOB B);
4. Unexplained atrophic kidney or size discrepancy .1.5 cm 
between kidneys (Class I, LOE B);
5. Sudden, unexplained pulmonary edema (Class I, LOE B);
6. Unexplained renal dysfunction, including patients start-
ing renal replacement treatment (Class IIA, LOE B);
7. Multivessel coronary artery disease or peripheral arterial 
disease (Class IIB, LOE B); and
8. Unexplained congestive heart failure or refractory angina 
(Class IIB, LOE C).
Although these clinical clues are useful in diagnosing 
patients with RAS, the Joint National Committee states that 
“more extensive testing in patients with identifiable causes of 
ARAS is typically not necessary unless blood pressure control 
is not achieved while the patient is receiving maximal antihy-
pertensive therapy”.1
Several methods had been used as screening tools to 
help with the detection of ARAS, which include, but are 
not limited to: “magnetic resonance angiography (MRA), 
helical computed tomographic angiography (CTA), Doppler 
ultrasonography, renal scintigraphy (captopril scan), invasive 
angiography, peripheral renin levels, and renal vein renin 
sampling”.1 In order for an individual imaging study to be 
considered optimal, they must meet certain objectives like 
“characterization on the basis of anatomic and hemodynamic 
severity of ARAS, anatomic consequences on the artery and 
on the kidney itself, functional and cellular consequences of 
ARAS on the kidney and identification of criteria associated 
with renal impairment related to renovascular disease”.1 The 
test of choice will basically depend on the local availability and 
clinical expertise.
Ultrasonography is the primary imaging study used to 
detect ARAS. Its benefits are that it is widely available, safe, 
and inexpensive, but results depend on the operator and have 
suboptimal accuracy that ranges from 60% to 90%.1 In RAS, 
“spectral broadening and increased velocity on ultrasound 
are markers of hemodynamically significant stenosis. When 
using duplex Doppler ultrasonography, utilization of the renal 
resistive index can predict the outcome after revascularization, 
showing that a higher resistive index is associated with dimin-
ished predicted benefit from revascularization.1 In a study of 
RAS in young female without FMD
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almost 6000 patients with hypertension and clinical features, 
suggestive of atherosclerotic renovascular disease, 131 patients 
who had RAS and underwent technically successful angio-
plasty had poor outcomes with a resistive index of 0.5. Out-
comes were better among the 96 patients with a resistive index 
of less than 0.5.4 Thus, this is not a broadly useful parameter 
for predicting outcome after revascularization.
CTA is another important tool utilized to aid in the 
diagnosis of RAS; however, CTA is contraindicated in 
patients with contrast allergy and has the possibility of caus-
ing contrast-induced nephropathy in patients with impaired 
renal function.1 CTA can detect small accessory renal arter-
ies because of high spatial resolution, and this modality is 
preferred in many clinical situations (eg, implanted devices, 
claustrophobia) but has “less specificity than MRA for detect-
ing hemodynamically significant ARAS”.1
Using arteriography as the gold standard, MRA has a 
reported sensitivity and specificity of 90% and 100%, respec-
tively. It does not require the use of iodinated contrast or radi-
ation, resulting in lower contrast reactions; however, there are 
concerns about gadolinium-associated complications includ-
ing nephrogenic systemic fibrosis, which have greatly reduced 
its application for renovascular disease, primarily in patients 
with reduced renal function.1
Angiography is helpful in evaluating a patient with 
ARAS, as it assesses the severity and detects intrarenal vas-
cular abnormalities and anatomic abnormalities. It is true that 
using “digital subtraction angiography improves contrast reso-
lution and may decrease the volume of contrast needed to as 
little as 15 mL, but because it is invasive there are several risks 
such as arterial puncture and manipulation of catheter/wire, it 
can result in arterial trauma, spasm or thromboembolic phe-
nomena; however, it has the advantage that in patients with 
renal impairment or contrast allergy, carbon dioxide can be 
used to avoid nephrotoxicity”.1
Because of the potential for harm from invasive pro-
cedures, only those patients who are thought to have high 
likelihood of benefiting from the procedure are tested. These 
include patients with failure of optimal medical therapy with 
secondary causes being evaluated, intolerance to optimal med-
ical therapy, and suspected fibromuscular disease in a young 
person in an attempt to limit the need for lifelong antihyper-
tensive therapy.
treatment: medical therapy vs revascularization. Medi-
cal therapy and revascularization approach have been used for 
the management of RAS. These patients necessitate thorough 
medical therapy. “Angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers are recommended for 
controlling hypertension and reducing clinical events in those 
with known cardiovascular disease.” But its use is with caution, 
as it may progress to overt renal failure, especially in patients 
with severe bilateral RAS or advanced chronic kidney disease.5
A more controversial area is the use of renal artery revas-
cularization as a therapeutic option in these patients with RAS. 
The 2006 American College of Cardiology/American Heart 
Association (ACC/AHA) guidelines on peripheral artery dis-
ease state that testing for RAS is only indicated if a corrective 
procedure is to be performed once clinically significant renovas-
cular disease is detected. In the medical literature, it is shown 
that patients with incidentally discovered ARAS do not require 
therapy directed at the renal vasculature since there is evidence 
that renal artery revascularization in such patients does not 
improve blood pressure or other outcomes in this setting.1
Several small-randomized control trials in the 1990s 
demonstrated only minor differences in BP attributable to 
revascularization, although crossover rates from medical ther-
apy arms were substantial, ranging from 24% to 44%.5 The 
Stent Placement for Atherosclerotic Renal Artery Stenosis 
(STAR) and Angioplasty and Stenting for Renal Atheroscle-
rotic Lesions (ASTRAL) were published in 2009 in the gene-
ral medical literature. Both of these studies concluded that 
revascularization for atherosclerotic renovascular disease pro-
vides no benefit. Recent studies also indicate that after renal 
artery stent placement, inflammatory injury markers and GFR 
do not recover, despite increasing blood flow and reversing tis-
sue hypoxia.3
Antihypertensive drugs can effectively control the blood 
pressure in many patients with renovascular hypertension, and 
it is unclear that correction of a stenosis (with either percu-
taneous or surgical therapy) frequently results in additional 
long-term benefit. Also, consistent use of statins, balanced 
glycemic control, and smoking cessation counseling are of 
great significance. The ongoing randomized, multicenter Car-
diovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) 
trial is evaluating whether or not percutaneous revasculariza-
tion of renovascular disease is superior to optimal therapy in 
preventing cardiovascular outcomes.1 The CORAL results 
show that renal artery stenting does not reduce adverse out-
comes in patients that present with ARAS and hypertension or 
chronic kidney disease, compared with medical therapy alone. 
Although associated with a modest reduction in systolic blood 
pressure, stenting does not reduce the risk of cardiovascular or 
renal events.3
Renal artery stenting procedures have significantly 
increased as one approach to treat this clinical problem. Devel-
oping both noninvasive and invasive predictive tools to better 
identify which patient will respond to renal revascularization 
will also be beneficial.4
Conclusion
ARAS is not common in young females. RAS is a medical 
condition with complex pathophysiology that involves early 
recognition and effective medical therapy to prevent future 
cardiovascular events. This is still a problem for clinicians 
with no clear consensus on how to investigate and assess the 
clinical significance of stenotic lesions and manage the find-
ings. RAS caused by FMD is likely more common than previ-
ously appreciated that should be actively looked for in younger 
Peralta et al
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hypertensive patients and can be managed successfully with 
angioplasty.5
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